ASCO 2024: aanbevolen abstracten gerelateerd aan longkanker en asbestkanker (mesothelioma) door vooraanstaande oncologen wereldwijd

Aanbevolen abstracten van ASCO 2024 specifiek gerelateerd aan longkanker en mesothelioma - asbestkanker door artsen die of zelf voor ASCO werken of door ASCO zijn gevraagd naar hun tips voor belangrijke studies.

Alle abstracten gerelateerd aan loco regionale longkanker en asbestkanker - mesothelioma staan in deze PDF maar zijn 129 abstracten. Voor uitgezaaide longkanker zijn het er nog meer 168 abstracten, klik daarvoor op deze PDF.

Voor de aanbevolen abstracten door vooraanstaande oncologen wereldwijd klik op de nummers vooraan de omschrijving van de abstracten.

Eerst abstracten aanbevolen door Dr. Jean-Yves Douillard, Professor Emeritus of Medical Oncology at the University of Nantes, France, and member of the Advisory Board of PracticeUpdate Oncology:

Friday, May 31, 2024; 2:45 PM–5:45 PM CDT
Oral Abstract Session
Lung Cancer—Non–Small Cell Metastatic

8504 Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study. E Felip, BC Cho, V Gutiérrez, et al

Sunday, June 2, 2024; 1:00 PM–4:00 PM CDT
Plenary Session
Local–Regional Non–Small Cell Lung Cancer

LBA4 Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. SS Ramalingam, T Kato, X Dong, et al

LBA5 ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). DR Spigel, Y Cheng, BC Cho, et al

Dr. David Henry, Clinical Professor of Medicine at Pennsylvania Hospital in Philadelphia, and member of the Advisory Board of PracticeUpdate Oncology, beveelt deze abstracten aan:

Friday, May 31, 2024; 2:45 PM–5:45 PM CDT
Oral Abstract Session
Lung Cancer—Non–Small Cell Metastatic

LBA8500 Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. LG Paz-Ares, O Juan- Vidal, GS Mountzios, et al

Reported here is a potential new approach to the treatment of metastatic NSCLC using a drug–antibody conjugate that targets a novel biomarker in patients with lung cancer who have failed immunotherapy and chemotherapy.

Sunday, June 2, 2024; 7:30 AM–8:00 AM CDT
Oral Abstract Session
Breast Cancer, Special Sessions

LBA1000 Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). G Curigliano, X Hu, R Dent, et al

This study supports the evidence of the superiority of trastuzumab deruxtecan versus other therapies for HER2-positive metastatic breast cancer. This is a very effective regimen for even those patients with HER2-low disease.

Sunday, June 2, 2024; 8:00 AM–11:00 AM CDT
Oral Abstract Session
Gastrointestinal Cancer—Colorectal and Anal

3503 Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW. HJ Lenz, S Lonardi, E Elez, et al

Presented are further results and an update of the primary treatment approach to MSI-high colorectal cancer using combination immunotherapy of ipilimumab/nivolumab versus chemotherapy, a novel approach that continues to yield better results.

ASCO 2024, longkanker, mesothelioma, asbestkanker, aanbevolen abstracten